SALIM VIRANI to Eligibility Determination
This is a "connection" page, showing publications SALIM VIRANI has written about Eligibility Determination.
Connection Strength
1.440
-
Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
Score: 0.635
-
Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
Score: 0.559
-
Statin Eligibility, Coronary Artery Calcium, and Subsequent Cardiovascular Events According to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Heart Assoc. 2018 06 13; 7(12).
Score: 0.151
-
Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. Am Heart J. 2018 01; 195:151-152.
Score: 0.036
-
Implications of the LEGACY trial on US Atrial Fibrillation Patients: An NCDR Research to Practice (R2P) Project. Am J Cardiol. 2017 02 15; 119(4):579-584.
Score: 0.034
-
Medicare eligibility and physician utilization among adults with coronary heart disease and stroke. Med Care. 2012 Jun; 50(6):547-53.
Score: 0.025